Noboru Yamamoto Selected Research

amrubicin

11/2019	Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer.
1/2017	Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
1/2017	Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011).
9/2016	Simultaneous optimization of limited sampling points for pharmacokinetic analysis of amrubicin and amrubicinol in cancer patients.
10/2015	Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.
4/2014	A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901).
12/2012	Gender difference in hematological toxicity among lung cancer patients receiving amrubicin monotherapy.
4/2012	Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer.
7/2011	Amrubicin monotherapy for patients with previously treated advanced large-cell neuroendocrine carcinoma of the lung.
3/2010	Simple and sensitive HPLC method for determination of amrubicin and amrubicinol in human plasma: application to a clinical pharmacokinetic study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Noboru Yamamoto Research Topics

Disease

146	Neoplasms (Cancer) 03/2022 - 01/2002
85	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2022 - 02/2002
22	Disease Progression 05/2022 - 07/2006
20	Neutropenia 10/2020 - 02/2005
20	Lung Neoplasms (Lung Cancer) 11/2019 - 08/2005
14	Diarrhea 01/2021 - 11/2006
11	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2021 - 06/2004
10	Exanthema (Rash) 01/2022 - 01/2010
10	Carcinoma (Carcinomatosis) 01/2022 - 08/2005
10	Nausea 01/2021 - 06/2003
9	Hypertension (High Blood Pressure) 01/2022 - 11/2006
9	Neoplasm Metastasis (Metastasis) 01/2020 - 05/2007
8	Thrombocytopenia (Thrombopenia) 12/2015 - 10/2005
7	Adenocarcinoma of Lung 12/2020 - 12/2008
7	Leukopenia 12/2015 - 10/2005
6	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2021 - 07/2004
6	Thymoma (Thymic Carcinoma) 10/2020 - 08/2011
6	Vomiting 01/2020 - 06/2003
6	Proteinuria 01/2018 - 11/2009
5	Fatigue 01/2021 - 06/2003
5	Stomatitis 05/2020 - 08/2010
4	Anorexia 01/2021 - 08/2010
4	Fever (Fevers) 12/2020 - 07/2006
4	Thymus Neoplasms (Thymus Neoplasm) 06/2020 - 08/2011
4	Sleepiness 01/2020 - 08/2010
4	Melanoma (Melanoma, Malignant) 06/2019 - 10/2016
3	Lymphoma (Lymphomas) 01/2022 - 12/2020
3	Drug-Related Side Effects and Adverse Reactions 12/2021 - 04/2005
3	Febrile Neutropenia 01/2020 - 07/2014
3	Radiation Pneumonitis 01/2020 - 07/2006
3	Breast Neoplasms (Breast Cancer) 01/2018 - 06/2012
3	Headache (Headaches) 04/2017 - 11/2006
3	Pancreatic Neoplasms (Pancreatic Cancer) 10/2016 - 04/2005
2	Pneumonia (Pneumonitis) 10/2022 - 01/2012
2	Colorectal Neoplasms (Colorectal Cancer) 12/2021 - 01/2018
2	Osteosarcoma (Osteogenic Sarcoma) 12/2021 - 02/2014
2	COVID-19 08/2021 - 12/2020
2	Pruritus (Itching) 01/2021 - 10/2012

Drug/Important Bio-Agent (IBA)

24	Cisplatin (Platino)FDA LinkGeneric 10/2021 - 02/2002
22	ErbB Receptors (EGF Receptor)IBA 01/2022 - 10/2005
20	Paclitaxel (Taxol)FDA LinkGeneric 01/2017 - 12/2003
18	PlatinumIBA 01/2022 - 10/2003
17	Pharmaceutical PreparationsIBA 03/2022 - 01/2002
15	Tyrosine Kinase InhibitorsIBA 01/2021 - 03/2008
14	Irinotecan (Camptosar)FDA LinkGeneric 01/2017 - 01/2002
13	NivolumabIBA 01/2022 - 11/2016
13	Biomarkers (Surrogate Marker)IBA 12/2021 - 04/2011
13	Carboplatin (JM8)FDA LinkGeneric 01/2017 - 09/2005
11	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2022 - 03/2008
11	Alanine Transaminase (SGPT)IBA 01/2021 - 12/2003
11	Gefitinib (Iressa)FDA Link 05/2020 - 07/2004
10	amrubicinIBA 11/2019 - 03/2010
9	pembrolizumabIBA 10/2022 - 01/2020
9	Immune Checkpoint InhibitorsIBA 03/2022 - 03/2016
8	B7-H1 AntigenIBA 03/2022 - 09/2015
8	Aspartate Aminotransferases (Aspartate Transaminase)IBA 12/2021 - 10/2005
8	Phosphotransferases (Kinase)IBA 12/2021 - 05/2011
7	Monoclonal AntibodiesIBA 01/2022 - 03/2014
7	Docetaxel (Taxotere)FDA Link 01/2019 - 10/2003
6	LigandsIBA 01/2021 - 01/2016
6	Gemcitabine FDA Link 06/2013 - 02/2002
4	Bevacizumab (Avastin)FDA Link 01/2022 - 10/2014
4	EnzymesIBA 01/2021 - 02/2005
4	CrizotinibIBA 01/2021 - 08/2016
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2020 - 11/2009
4	lenvatinibIBA 01/2020 - 04/2011
4	Olanzapine (Zyprexa)FDA Link 01/2020 - 02/2015
4	Pemetrexed (MTA)FDA Link 01/2020 - 07/2010
4	Antineoplastic Agents (Antineoplastics)IBA 01/2020 - 08/2006
4	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 02/2016
4	amrubicinolIBA 11/2019 - 03/2010
4	Proteins (Proteins, Gene)FDA Link 01/2019 - 04/2006
4	CreatinineIBA 01/2019 - 12/2009
3	alectinibIBA 05/2022 - 01/2017
3	durvalumabIBA 01/2022 - 05/2019
3	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 07/2021 - 01/2020
3	vandetanib (ZD6474)IBA 01/2021 - 11/2006
3	AntibodiesIBA 01/2021 - 09/2004
3	osimertinibIBA 12/2020 - 07/2017
3	Etoposide (VP 16)FDA LinkGeneric 01/2017 - 04/2014
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 12/2015 - 05/2011
3	Hemoglobins (Hemoglobin)IBA 08/2015 - 08/2006
3	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 07/2014 - 10/2010
3	Vinorelbine (Navelbine)FDA LinkGeneric 08/2013 - 08/2004
3	Cytochrome P-450 CYP3AIBA 08/2008 - 02/2005
2	tremelimumabIBA 01/2022 - 01/2016
2	eribulin FDA Link 01/2022 - 01/2021
2	Investigational DrugsIBA 01/2022 - 03/2016
2	AntigensIBA 01/2022 - 04/2021
2	TAS-116IBA 12/2021 - 01/2019
2	4- (2- fluoro- 4- ((((2- phenylacetyl)amino)thioxomethyl)amino)phenoxy)- 7- methoxy- N- methyl- 6- quinolinecarboxamideIBA 12/2021 - 01/2020
2	Circulating Tumor DNAIBA 09/2021 - 01/2021

Therapy/Procedure

65	Therapeutics 03/2022 - 07/2004
59	Drug Therapy (Chemotherapy) 03/2022 - 02/2002
17	Radiotherapy 01/2021 - 07/2004
14	Chemoradiotherapy 01/2022 - 03/2007
4	Intravenous Infusions 02/2016 - 04/2008
3	Immunotherapy 06/2020 - 01/2018
3	Combination Drug Therapy (Combination Chemotherapy) 04/2016 - 07/2007
2	Genomic Medicine 07/2021 - 09/2018